Thursday, November 12, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· October 26, 2026

AudioEye expects Q4 adjusted EBITDA run rate over $17M, supported by AI efficiencies and new products

View original at seekingalpha.com
“On leverage and liquidity, Domeyer said, "We ended the quarter with $9.3 million in cash,"”
Verbatim excerpt from the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Litigation expense decreased in Q3, expected to fall further in Q4 and continue trending down

    60% confidence
  • Company has ramped revenue without ramping expenses for years and expects this to continue

    60% confidence
  • Full-year 2026 adjusted EBITDA guidance raised from at least $12.7M to $13.4M-$13.6M

    60% confidence
  • New agentic products can be purchased stand-alone or as an add-on

    60% confidence
  • AI-product demand is early; feedback very positive; some customer education needed

    60% confidence
  • Expects approximately 50% growth in adjusted EBITDA in 2026

    60% confidence
  • Expects to maintain the ~550bp gross margin improvement and look for room to expand

    60% confidence
  • Record revenue, record adjusted EBITDA, strong free cash flow and positive GAAP net income driven by efficiencies and increased AI use

    60% confidence
  • Hawaii's Act 257 has significant implications for travel and hospitality with deadlines 24 to 36 months after rules are final

    60% confidence
  • Best lead volume to date; litigation growing at record levels

    60% confidence
  • Q4 2026 revenue expected between $11.4M and $11.6M; FY2026 revenue narrowed to $43.6M-$43.8M

    60% confidence
  • Analysts note people worry about AI becoming a competitive threat

    60% confidence
  • Q4 2026 adjusted EBITDA expected $4.2M-$4.4M and adjusted EPS $0.32-$0.33

    60% confidence
  • About 12% YoY ARR growth expected to continue into Q4, driven by near-record new and expansion business, new products and EU enforcement

    60% confidence
  • AI has not created notable new competitors; proprietary dataset cannot be replicated

    60% confidence
  • Q4 adjusted EBITDA annualized run rate expected over $17M, up from $15M, equating to adjusted EPS run rate of around $1.30

    60% confidence
  • Agentic Audits find about 50% more high-severity issues than automation, though manual audit is still needed

    60% confidence
  • Comfortable with cash levels; significant cash generation expected in Q4 and 2027; no issues with debt provider on buyback

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
AudioEye expects Q4 adjusted EBITDA run rate over $17M, supported by AI efficiencies and new products — Source | Via News | Via News